Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 14/20 | 0.64 |
| ▸ | DRD2 | P14416 | 6/20 | 0.64 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 5/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107494 | 0.94 | SLC6A12 (0.66) | DRD4DRD2MCHR1DRD3SIGMAR1 | |
| SCHEMBL14205010 | 0.84 | POLB (0.58) | DRD4DRD2MCHR1DRD3SIGMAR1 | |
| SCHEMBL1753725 | 0.84 | DRD4 (0.77) | DRD4DRD2MCHR1DRD3SIGMAR1 | |
| SCHEMBL8706525 | 0.79 | CCR3 (0.73) | DRD4DRD2SIGMAR1POLB | |
| SCHEMBL14205981 | 0.79 | POLB (0.65) | DRD4DRD2MCHR1DRD3SIGMAR1 | |
| SCHEMBL2900272 | 0.78 | SIGMAR1 (0.86) | DRD4DRD2MCHR1DRD3SIGMAR1 | |
| SCHEMBL1753373 | 0.78 | DRD4 (0.51) | DRD4DRD2DRD3SIGMAR1 | |
| SCHEMBL10107601 | 0.77 | SLC6A12 (0.83) | DRD4DRD2MCHR1DRD3SIGMAR1 | |
| SCHEMBL8711818 | 0.76 | DRD4 (0.71) | DRD4DRD2SIGMAR1POLB | |
| SCHEMBL7694198 | 0.76 | DRD2 (0.85) | DRD4DRD2MCHR1SIGMAR1SLC6A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158783-B2 | MTP inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-8158783-B2 | MTP inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-20100016291-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016291-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016291-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | PNLIP, APOB, MTPN | DRD4 4420/4885DRD2 4546/4885MCHR1 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.